Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
China · Delayed Price · Currency is CNY 25.20
-0.33 (-1.29%)
Apr 28, 2026, 4:00 PM EDT
SHE:301246 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,939 | 1,742 | 2,026 | 2,046 | 1,568 |
Other Revenue | - | 28.69 | 28.87 | 17.73 | 9.44 |
| 1,939 | 1,771 | 2,055 | 2,064 | 1,578 | |
Revenue Growth (YoY) | 9.53% | -13.83% | -0.43% | 30.79% | 21.10% |
Cost of Revenue | 1,575 | 1,590 | 1,814 | 1,622 | 1,051 |
Gross Profit | 364.15 | 180.95 | 240.49 | 442.18 | 526.52 |
Selling, General & Admin | 110.23 | 91.38 | 98.5 | 102.96 | 108.41 |
Research & Development | 83.9 | 59.18 | 68.82 | 64.01 | 48.71 |
Other Operating Expenses | -8.38 | -5.4 | 11.79 | 9.46 | 12.27 |
Operating Expenses | 185.74 | 145.67 | 176.55 | 180.73 | 170.42 |
Operating Income | 178.41 | 35.28 | 63.94 | 261.45 | 356.11 |
Interest Expense | - | -12 | -13.4 | -3.41 | -2.38 |
Interest & Investment Income | 31.06 | 14.12 | 36.47 | 172.05 | 192.11 |
Currency Exchange Gain (Loss) | - | 5.63 | 1.11 | 13.64 | -2.62 |
Other Non Operating Income (Expenses) | -26.29 | -1.73 | -8.43 | -3.09 | -1.02 |
EBT Excluding Unusual Items | 183.18 | 41.31 | 79.69 | 440.65 | 542.21 |
Impairment of Goodwill | - | - | - | - | -6.5 |
Gain (Loss) on Sale of Investments | 1.85 | 3.82 | 2.86 | - | - |
Gain (Loss) on Sale of Assets | 0.77 | 0.27 | 0.57 | 14.44 | -0.62 |
Asset Writedown | -40.09 | - | - | -1.97 | -0.76 |
Other Unusual Items | - | 14.3 | 15.44 | 24.85 | 10.72 |
Pretax Income | 145.72 | 59.69 | 98.56 | 477.98 | 545.04 |
Income Tax Expense | 28.09 | 8.23 | 11.39 | 43.18 | 51.19 |
Earnings From Continuing Operations | 117.63 | 51.46 | 87.17 | 434.8 | 493.85 |
Minority Interest in Earnings | 1.42 | 0 | - | - | - |
Net Income | 119.05 | 51.47 | 87.17 | 434.8 | 493.85 |
Net Income to Common | 119.05 | 51.47 | 87.17 | 434.8 | 493.85 |
Net Income Growth | 131.33% | -40.96% | -79.95% | -11.96% | 92.02% |
Shares Outstanding (Basic) | 397 | 399 | 388 | 353 | 353 |
Shares Outstanding (Diluted) | 397 | 399 | 388 | 353 | 353 |
Shares Change (YoY) | -0.42% | 2.71% | 10.02% | -0.00% | 0.13% |
EPS (Basic) | 0.30 | 0.13 | 0.22 | 1.23 | 1.40 |
EPS (Diluted) | 0.30 | 0.13 | 0.22 | 1.23 | 1.40 |
EPS Growth | 132.30% | -42.52% | -81.78% | -11.96% | 91.78% |
Free Cash Flow | -341.06 | -176.01 | -439.39 | -292.1 | -62.92 |
Free Cash Flow Per Share | -0.86 | -0.44 | -1.13 | -0.83 | -0.18 |
Dividend Per Share | - | 0.030 | 0.050 | 0.100 | - |
Dividend Growth | - | -40.00% | -50.00% | - | - |
Gross Margin | 18.78% | 10.22% | 11.70% | 21.43% | 33.37% |
Operating Margin | 9.20% | 1.99% | 3.11% | 12.67% | 22.57% |
Profit Margin | 6.14% | 2.91% | 4.24% | 21.07% | 31.30% |
Free Cash Flow Margin | -17.59% | -9.94% | -21.38% | -14.15% | -3.99% |
EBITDA | 379.92 | 212.99 | 220.09 | 350.53 | 435.77 |
EBITDA Margin | 19.59% | 12.03% | 10.71% | 16.98% | 27.62% |
D&A For EBITDA | 201.51 | 177.71 | 156.16 | 89.08 | 79.66 |
EBIT | 178.41 | 35.28 | 63.94 | 261.45 | 356.11 |
EBIT Margin | 9.20% | 1.99% | 3.11% | 12.67% | 22.57% |
Effective Tax Rate | 19.27% | 13.79% | 11.56% | 9.03% | 9.39% |
Revenue as Reported | - | 1,771 | 2,055 | 2,064 | 1,578 |
Advertising Expenses | - | 1.03 | 0.8 | 0.02 | 0.69 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.